

Global Biologics Market Size study, by Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-Based Biologics, Gene-Based Biologics, and Other Products), by Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Other Applications) and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/GDD92751C61EEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: GDD92751C61EEN

Abstracts

Global Biologics Market is valued at approximately USD 338.04 billion in 2023 and is anticipated to grow with a robust compound annual growth rate of more than 10.49% over the forecast period 2024–2032. Biologics, which have fundamentally reshaped the landscape of modern medicine, are rapidly transcending the traditional pharmaceutical boundaries by targeting diseases at the molecular and cellular levels. Built from living organisms or their components, these therapies—ranging from monoclonal antibodies to gene and cell-based treatments—offer unprecedented precision in treating complex, chronic, and previously untreatable conditions. The biologics sector continues to expand its footprint across therapeutic areas such as oncology, immunology, and rare diseases, propelled by both scientific breakthroughs and patient-centric treatment protocols.

Driving this momentum is the continuous evolution in biomanufacturing capabilities, regulatory streamlining, and increasing healthcare investments across the globe. Advancements in recombinant DNA technology and personalized medicine have empowered biopharmaceutical companies to roll out targeted therapies with fewer off-target effects. Moreover, rising incidences of autoimmune disorders and cancer, coupled with the need for safer and more efficacious treatment options, have fueled the adoption of biologics in both developed and emerging economies. Government initiatives promoting biosimilars for cost-containment and improved accessibility are

further boosting the market trajectory. However, challenges related to high production costs, cold chain logistics, and immunogenicity risks still pose significant hurdles for widespread implementation.

Leading pharmaceutical firms are leveraging cutting-edge platforms such as CRISPR, mRNA, and AI-driven drug discovery to unlock next-generation biologics. Simultaneously, partnerships between biotech start-ups and pharmaceutical giants are catalyzing the pace of innovation and commercialization. The sector is also witnessing a transition toward decentralized manufacturing and single-use bioreactor systems, which reduce contamination risk and expedite production. Furthermore, the biologics value chain is increasingly focusing on post-approval lifecycle management, real-world evidence integration, and expansion into subcutaneous and oral delivery formats, enhancing patient compliance and broadening therapeutic reach.

Health policy reforms across various geographies are aligning incentives toward biologics innovation and reimbursement. For instance, regulatory bodies in the U.S., EU, and Japan are fast-tracking approvals under accelerated pathways to address urgent unmet medical needs. Meanwhile, biosimilar competition is intensifying, especially for blockbuster biologics approaching patent cliffs, offering a cost-effective option for payers and boosting market penetration. Emerging countries are also scaling domestic biologics production through public-private collaborations, R&D grants, and technology transfers, ushering in an era of inclusive growth and equitable access to high-end therapeutics.

Regionally, North America dominates the global biologics market, attributed to its strong innovation ecosystem, sophisticated regulatory infrastructure, and a high prevalence of chronic illnesses. Europe trails closely, marked by a unified regulatory framework, biosimilar adoption, and public funding for biologics research. The Asia Pacific region is expected to witness the fastest growth, underpinned by a burgeoning middle class, increasing investment in biopharmaceutical infrastructure, and regional efforts to build competitive biologics pipelines. Latin America and the Middle East & Africa are gradually evolving, backed by improving healthcare access, growing clinical trial activity, and a surge in biologics imports.

Major market player included in this report are:

Pfizer Inc.

AbbVie Inc.

Roche Holding AG

Merck & Co., Inc.

Amgen Inc.

Eli Lilly and Company

Sanofi S.A.

Johnson & Johnson

Bristol-Myers Squibb Company

AstraZeneca PLC

Biogen Inc.

Novartis AG

Gilead Sciences, Inc.

Takeda Pharmaceutical Company Limited

Regeneron Pharmaceuticals, Inc.

The detailed segments and sub-segment of the market are explained below:

By Product

Monoclonal Antibodies

Vaccines

Recombinant Hormones/Proteins

Cellular-Based Biologics

Gene-Based Biologics

Other Products

By Application

Cancer

Infectious Diseases

Autoimmune Diseases

Other Applications

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical Year – 2022

Base Year – 2023

Forecast Period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL BIOLOGICS MARKET EXECUTIVE SUMMARY

- 1.1. Global Biologics Market Size & Forecast (2022 – 2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Product
 - 1.3.2. By Application
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL BIOLOGICS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Payer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Reimbursement Dynamics
 - 2.3.4.4. Patient Awareness & Adoption
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL BIOLOGICS MARKET DYNAMICS

- 3.1. Market Drivers

- 3.1.1. Surging prevalence of chronic and rare diseases
- 3.1.2. Advancements in personalized and targeted therapies
- 3.1.3. Biosimilar adoption for cost containment
- 3.2. Market Challenges
 - 3.2.1. High manufacturing and cold-chain logistics costs
 - 3.2.2. Regulatory complexity and long development cycles
- 3.3. Market Opportunities
 - 3.3.1. Expansion in emerging markets
 - 3.3.2. Next-generation modalities (gene and cell therapies)
 - 3.3.3. Digital health integration in lifecycle management

CHAPTER 4. GLOBAL BIOLOGICS MARKET INDUSTRY ANALYSIS

- 4.1. Porter's 5-Force Model
 - 4.1.1. Bargaining Power of Suppliers
 - 4.1.2. Bargaining Power of Buyers
 - 4.1.3. Threat of New Entrants
 - 4.1.4. Threat of Substitutes
 - 4.1.5. Competitive Rivalry
 - 4.1.6. Futuristic Approach to Porter's 5 Force Model
 - 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
 - 4.2.1. Political
 - 4.2.2. Economic
 - 4.2.3. Social
 - 4.2.4. Technological
 - 4.2.5. Environmental
 - 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL BIOLOGICS MARKET SIZE & FORECASTS BY PRODUCT 2022–2032

- 5.1. Segment Dashboard
- 5.2. Global Biologics Market: Product Revenue Trend Analysis, 2022 & 2032 (USD)

Billion)

- 5.2.1. Monoclonal Antibodies
- 5.2.2. Vaccines
- 5.2.3. Recombinant Hormones/Proteins
- 5.2.4. Cellular-Based Biologics
- 5.2.5. Gene-Based Biologics
- 5.2.6. Other Products

CHAPTER 6. GLOBAL BIOLOGICS MARKET SIZE & FORECASTS BY APPLICATION 2022–2032

- 6.1. Segment Dashboard
- 6.2. Global Biologics Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
 - 6.2.1. Cancer
 - 6.2.2. Infectious Diseases
 - 6.2.3. Autoimmune Diseases
 - 6.2.4. Other Applications

CHAPTER 7. GLOBAL BIOLOGICS MARKET SIZE & FORECASTS BY REGION 2022–2032

- 7.1. North America Biologics Market
 - 7.1.1. U.S. Biologics Market
 - 7.1.1.1. Product breakdown size & forecasts, 2022–2032
 - 7.1.1.2. Application breakdown size & forecasts, 2022–2032
 - 7.1.2. Canada Biologics Market
- 7.2. Europe Biologics Market
 - 7.2.1. UK Biologics Market
 - 7.2.2. Germany Biologics Market
 - 7.2.3. France Biologics Market
 - 7.2.4. Spain Biologics Market
 - 7.2.5. Italy Biologics Market
 - 7.2.6. Rest of Europe Biologics Market
- 7.3. Asia Pacific Biologics Market
 - 7.3.1. China Biologics Market
 - 7.3.2. India Biologics Market
 - 7.3.3. Japan Biologics Market
 - 7.3.4. Australia Biologics Market

- 7.3.5. South Korea Biologics Market
- 7.3.6. Rest of Asia Pacific Biologics Market
- 7.4. Latin America Biologics Market
 - 7.4.1. Brazil Biologics Market
 - 7.4.2. Mexico Biologics Market
 - 7.4.3. Rest of Latin America Biologics Market
- 7.5. Middle East & Africa Biologics Market
 - 7.5.1. Saudi Arabia Biologics Market
 - 7.5.2. South Africa Biologics Market
 - 7.5.3. Rest of Middle East & Africa Biologics Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. Pfizer Inc.
 - 8.1.2. Roche Holding AG
 - 8.1.3. Amgen Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. Pfizer Inc.
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. AbbVie Inc.
 - 8.3.3. Merck & Co., Inc.
 - 8.3.4. Eli Lilly and Company
 - 8.3.5. Sanofi S.A.
 - 8.3.6. Johnson & Johnson
 - 8.3.7. Bristol-Myers Squibb Company
 - 8.3.8. AstraZeneca PLC
 - 8.3.9. Biogen Inc.
 - 8.3.10. Novartis AG

CHAPTER 9. RESEARCH PROCESS

- 9.1. Research Process
 - 9.1.1. Data Mining

- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes

I would like to order

Product name: Global Biologics Market Size study, by Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-Based Biologics, Gene-Based Biologics, and Other Products), by Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Other Applications) and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GDD92751C61EEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GDD92751C61EEN.html>